ACM
RYTM icon

Aster Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Aster Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40
Closed -$4.04K – 1382
2025
Q3 		$4.04K Buy
+40
New +$3.71K ﹤0.01% 824

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aster Capital Management's RYTM Position: Q4 2025 in Review

Aster Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 40 shares — an estimated $4.04K sold.

Aster Capital Management first reported a position in RYTM in Q3 2025 and held it in 1 quarter. The position peaked at $4.04K in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Aster Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Aster Capital Management sold 40 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $4.04K.
  • Aster Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Aster Capital Management's Rhythm Pharmaceuticals position peaked at $4.04K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Aster Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.